TriangleNCT00656513 · OUTCOME
Quality of Life (QOL) as Measured by the University of Washington Head and Neck Questionnaire (UWHNSS) Phase III
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- units on a scale
- Interval / dispersion
- Inter-Quartile Range
- Time frame
- Baseline and 9 months from randomization.
What was measured
The UWHNSS includes ten categories-pain, disfigurement, activity, recreation/entertainment, employment, eating, saliva, taste, speech, mucus/phlegm. Patient scores on the UWHNSS range from 0 to 100 with higher scores indicating declining quality of life. Change in total score was calculated by subtracting baseline from follow-up , thus a positive change score indicates a worsening while a negative change score indicates an improvement.
Analysis population: Eligible randomized patients with both baseline and 9-month UWHNSS total scores.
Groups in this outcome
Pilocarpine: Phase III
5mg pilocarpine by mouth 3 times a day for 12 weeks
ALTENS: Phase III
Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) twice weekly for 12 weeks via a Codetron unit
| Group | Source count |
|---|---|
| Pilocarpine: Phase III | 43 |
| ALTENS: Phase III | 51 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Pilocarpine: Phase III | -3.64 | Not reported | -9.09 | 1.82 | Not reported |
| ALTENS: Phase III | -7.27 | Not reported | -12.73 | -1.81 | Not reported |
Source statistical analyses
- group Ids
- OG000
- OG001
- non Inferiority Type
- SUPERIORITY
- p Value
- 0.14
- p Value Comment
- Two-sided test, significance level 0.05
- statistical Method
- t-test, 2 sided
Complete source fields
- analyses
- group Ids
- OG000
- OG001
- non Inferiority Type
- SUPERIORITY
- p Value
- 0.14
- p Value Comment
- Two-sided test, significance level 0.05
- statistical Method
- t-test, 2 sided
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- -9.09
- upper Limit
- 1.82
- value
- -3.64
- group Id
- OG001
- lower Limit
- -12.73
- upper Limit
- -1.81
- value
- -7.27
- denoms
- counts
- group Id
- OG000
- value
- 43
- group Id
- OG001
- value
- 51
- units
- Participants
- description
- The UWHNSS includes ten categories-pain, disfigurement, activity, recreation/entertainment, employment, eating, saliva, taste, speech, mucus/phlegm. Patient scores on the UWHNSS range from 0 to 100 with higher scores indicating declining quality of life. Change in total score was calculated by subtracting baseline from follow-up , thus a positive change score indicates a worsening while a negative change score indicates an improvement.
- dispersion Type
- Inter-Quartile Range
- groups
- description
- 5mg pilocarpine by mouth 3 times a day for 12 weeks
- id
- OG000
- title
- Pilocarpine: Phase III
- description
- Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) twice weekly for 12 weeks via a Codetron unit
- id
- OG001
- title
- ALTENS: Phase III
- param Type
- MEDIAN
- population Description
- Eligible randomized patients with both baseline and 9-month UWHNSS total scores.
- reporting Status
- POSTED
- time Frame
- Baseline and 9 months from randomization.
- title
- Quality of Life (QOL) as Measured by the University of Washington Head and Neck Questionnaire (UWHNSS) Phase III
- type
- SECONDARY
- unit Of Measure
- units on a scale
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice